Oryzon to present at upcoming international conferences
September 04, 2018 08:00 ET
|
Oryzon Genomics
Rodman & Renshaw 20th Annual Global Investment Conference, New York, USA19th International Conference on Alzheimer’s Drug Discovery, Jersey City, NJ, USABIO-SPAIN-2018, Sevilla, SPAINEuropean...
Oryzon to present at upcoming international conferences
August 06, 2018 11:06 ET
|
Oryzon Genomics
Gordon Research Conference of “Neurobiology of Brain Disorders” in Barcelona (Spain)Solebury Trout 8th Annual Hamptons CEO Roundtable in Bridgehampton, USA MADRID, Spain and CAMBRIDGE, Mass., Aug. ...
Oryzon to present at upcoming international conferences
July 02, 2018 09:45 ET
|
Oryzon Genomics
European Biotech Investor Day in NYC, New York, USAThe Alzheimer's Association International Conference AAIC- 2018 – Chicago, USA MADRID, Spain and CAMBRIDGE, Mass., July 02, 2018 (GLOBE...
ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
June 25, 2018 08:35 ET
|
Oryzon Genomics
MADRID, Spain and CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code:ES0167733015) (BME:ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to...
Oryzon to present at upcoming international conferences
June 01, 2018 08:00 ET
|
Oryzon Genomics
BIO International Convention 2018, Boston, Ma, USAJefferies 2018 Global Healthcare Conference, New York, USA14th Spring European Midcap Event, Paris, France MADRID, Spain and CAMBRIDGE, Mass., June...
ORYZON announces First Patients In ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
May 14, 2018 09:30 ET
|
Oryzon Genomics
The trial was approved in Spain in April and in France last week First three patients included in Spain last week This is the second Phase IIa study in a CNS indication with the drug ...
ORYZON Reports Financial Results and Corporate Update for the 1st Quarter 2018
May 09, 2018 09:33 ET
|
Oryzon Genomics
MADRID, Spain and CAMBRIDGE, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to...